Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Edoardo Crimini

Medical Oncologist

European Institute of Oncology

Italy

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Articles (20)

Year:

2026

Year:

2026

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (8)

Chiara Corti

Dana-Farber Cancer Institute

UNITED STATES

View details

Giuseppe Curigliano

European Institute of Oncology

ITALY

View details

Antonio Marra

Research Associate

Sloan Kettering Institute

UNITED STATES

View details

Pier Paolo Maria Berton Giachetti

European Institute of Oncology

ITALY

View details

Elisabetta Munzone

Director

European Institute of Oncology

ITALY

View details

Federica Giugliano

Institut Gustave Roussy

FRANCE

View details

Luca Boscolo Bielo

European Institute of Oncology

ITALY

View details

Liliana Ascione

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edoardo Crimini

Research Interests

Make your next move.

Explore related searches

Articles (20)

Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions

Role of Molecular Tumor Board in Pancreatic and Biliary Tract Tumors

Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting

Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population.

Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents.

Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations

Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers

Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

Molecular tumor board in patients with metastatic breast cancer.

Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate

Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study.

A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data

Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability

Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience

Variant allele frequency: a decision-making tool in precision oncology?

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?

Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer.

Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?

Collaborators (8)

Chiara Corti

Giuseppe Curigliano

Antonio Marra

Pier Paolo Maria Berton Giachetti

Elisabetta Munzone

Federica Giugliano

Luca Boscolo Bielo

Liliana Ascione

Make your next move.